Literature DB >> 19627632

The carboxy-terminus of merozoite surface protein 1: structure, specific antibodies and immunity to malaria.

A A Holder1.   

Abstract

Over the last 30 years, evidence has been gathered suggesting that merozoite surface protein 1 (MSP1) is a target of protective immunity against malaria. In a variety of experimental approaches using in vitro methodology, animal models and sero-epidemiological techniques, the importance of antibody against MSP1 has been established but we are still finding out what are the mechanisms involved. Now that clinical trials of MSP1 vaccines are underway and the early results have been disappointing, it is increasingly clear that we need to know more about the mechanisms of immunity, because a better understanding will highlight the limitations of our current assays and identify the improvements required. Understanding the structure of MSP1 will help us design and engineer better antigens that are more effective than the first generation of vaccine candidates. This review is focused on the carboxy-terminus of MSP1.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19627632     DOI: 10.1017/S0031182009990515

Source DB:  PubMed          Journal:  Parasitology        ISSN: 0031-1820            Impact factor:   3.234


  63 in total

1.  Plasmodium falciparum 19-kilodalton merozoite surface protein 1 (MSP1)-specific antibodies that interfere with parasite growth in vitro can inhibit MSP1 processing, merozoite invasion, and intracellular parasite development.

Authors:  David K Moss; Edmond J Remarque; Bart W Faber; David R Cavanagh; David E Arnot; Alan W Thomas; Anthony A Holder
Journal:  Infect Immun       Date:  2011-12-27       Impact factor: 3.441

2.  Isolation of viable Plasmodium falciparum merozoites to define erythrocyte invasion events and advance vaccine and drug development.

Authors:  Michelle J Boyle; Danny W Wilson; Jack S Richards; David T Riglar; Kevin K A Tetteh; David J Conway; Stuart A Ralph; Jake Baum; James G Beeson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-26       Impact factor: 11.205

3.  Production and preclinical evaluation of Plasmodium falciparum MSP-119 and MSP-311 chimeric protein, PfMSP-Fu24.

Authors:  Puneet K Gupta; Paushali Mukherjee; Shikha Dhawan; Alok K Pandey; Suman Mazumdar; Deepak Gaur; S K Jain; Virander S Chauhan
Journal:  Clin Vaccine Immunol       Date:  2014-04-30

4.  Humoral and cellular immunity to Plasmodium falciparum merozoite surface protein 1 and protection from infection with blood-stage parasites.

Authors:  Ann M Moormann; Peter Odada Sumba; Kiprotich Chelimo; Hua Fang; Daniel J Tisch; Arlene E Dent; Chandy C John; Carole A Long; John Vulule; James W Kazura
Journal:  J Infect Dis       Date:  2013-03-28       Impact factor: 5.226

5.  Suppressive and additive effects in protection mediated by combinations of monoclonal antibodies specific for merozoite surface protein 1 of Plasmodium yoelii.

Authors:  Irosoki Eslava; Gilberto Payares; Beatriz M Pernia; Anthony A Holder; Lilian M Spencer
Journal:  Malar J       Date:  2010-02-10       Impact factor: 2.979

6.  Quantitative analysis of immune response and erythropoiesis during rodent malarial infection.

Authors:  Martin R Miller; Lars Råberg; Andrew F Read; Nicholas J Savill
Journal:  PLoS Comput Biol       Date:  2010-09-30       Impact factor: 4.475

7.  Regulated maturation of malaria merozoite surface protein-1 is essential for parasite growth.

Authors:  Matthew A Child; Christian Epp; Hermann Bujard; Michael J Blackman
Journal:  Mol Microbiol       Date:  2010-02-08       Impact factor: 3.501

8.  Antigenic characterization of an intrinsically unstructured protein, Plasmodium falciparum merozoite surface protein 2.

Authors:  Christopher G Adda; Christopher A MacRaild; Linda Reiling; Kaye Wycherley; Michelle J Boyle; Vivian Kienzle; Paul Masendycz; Michael Foley; James G Beeson; Raymond S Norton; Robin F Anders
Journal:  Infect Immun       Date:  2012-09-10       Impact factor: 3.441

9.  Cellular responses to modified Plasmodium falciparum MSP119 antigens in individuals previously exposed to natural malaria infection.

Authors:  Christian M F Okafor; Chiaka I Anumudu; Yusuf O Omosun; Chairat Uthaipibull; Idowu Ayede; Henrietta O Awobode; Alex B Odaibo; Jean Langhorne; Anthony A Holder; Roseangela I Nwuba; Marita Troye-Blomberg
Journal:  Malar J       Date:  2009-11-23       Impact factor: 2.979

10.  Malaria vaccines: where next?

Authors:  Anthony A Holder
Journal:  PLoS Pathog       Date:  2009-10-30       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.